S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.

ABSTRACT

AIM: To assess the efficacy and safety of combination therapy based on S-1, a novel oral fluoropyrimidine, vs S-1 monotherapy in advanced gastric cancer (AGC). METHODS: We searched PubMed, EMBASE and the Cochrane Library for eligible studies published before March 2013. Our analysis identified four randomized controlled trials involving 790 participants with AGC. The outcome measures were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3-4 adverse events. RESULTS: Meta-analysis showed that S-1-based combination therapy significantly improved OS (HR = 0.77, 95%CI 0.66-0.91, P = 0.002), PFS (HR = 0.58, 95%CI 0.46-0.72, P = 0.000) and ORR (OR = 2.23, 95%CI 1.54-3.21, P = 0.000). Sensitivity analysis further confirmed this association. Lower incidence of grade 3-4 leucopenia (OR = 4.06, 95%CI 2.11-7.81), neutropenia (OR = 3.94, 95%CI 2.1-7.81) and diarrhea (OR = 2.41, 95%CI 1.31-4.44) was observed in patients with S-1 monotherapy. CONCLUSION: S-1-based combination therapy is superior to S-1 monotherapy in terms of OS, PFS and ORR. S-1 monotherapy is associated with less toxicity.